Zentalis Finalizes Cancer Drug Dose, Jefferies Raises Price Target

Zentalis (ZNTL) has successfully locked in the dosage for its cancer drug, a development that has led Jefferies to raise its price target for the company's stock. This indicates positive progress in their clinical development.